Canbridge Pharmaceuticals (HKSE:01228) Dividends per Share : HK$0.00 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Dividends per Share?

Canbridge Pharmaceuticals's dividends per share for the six months ended in Dec. 2024 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00. As of today, Canbridge Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Canbridge Pharmaceuticals Dividends per Share Historical Data

The historical data trend for Canbridge Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Dividends per Share Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Dividends per Share	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Canbridge Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Canbridge Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Canbridge Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Canbridge Pharmaceuticals (HKSE:01228) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Canbridge Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.491
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Canbridge Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner
Xue James Qun	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines